Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 2, 2006, Pages 83-92

  Migoya, Elizabeth M ^a   Bergman, A ^a   Hreniuk, D ^a   Matthews, N ^b   Yi, B ^a   Roadcap, B ^a   Valesky, R ^a   Liu, L ^a   Riffel, K ^a   Groff, M ^a   Zhao, J J ^a   Musson, D G ^a   Gambale, J ^a   Kosoglou, T ^a   Statkevich, P ^a   Lasseter, K C ^c   Laurent, A ^d   Johnson Levonas, A O ^a   Murphy, G ^a   Gottesdiener, K ^a   Paolini, J F ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SFBC International   (United States)

^d Pharmaceutical Product Development   (United States)

Author keywords

Bioequivalence; Coadministration; Ezetimibe; Simvastatin; Tablet

Indexed keywords

CREATININE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; LIVER DYSFUNCTION; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET;

EID: 32544448046     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44083     Document Type: Article

References (41)

1. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R et al 2003 Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107: 2409-2415
2. Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R et al 2004a Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolemia. Int J Clin Pract 58: 653-658
3. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J 2004b Efficacy and safety of ezetimibe coadministered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 93: 1487-1494
4. Bays H 2002 Ezetimibe. Expert Opin Investig Drugs 11: 1587-1604
5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504
6. Castelli WP 1984 Epidemiology of coronary heart disease: the Framingham study. Am J Med 76: 4-12
7. Cesari M, Maiolino G, Colonna S, Zanchetta M, Pedon L, Maiolino P et al 2003 Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. J Cardiovasc Pharmacol 42: 484-490
8. Chow SC, Liu JP 1992 Design and analysis of bioavailability and bioequivalence studies. Marcel Dekker, New York, p 163
9. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP et al 2002 Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40: 2125-2134
10. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L et al 2004 Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 58: 746-755
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622
12. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R et al 2002 Efficacy and safety of a potent new selective cholesterol absorption inhibitor, czetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90: 1092-1097
13. Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK 2001 A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23: 871-885
14. Food and Drug Administration 1998 Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions - FDA. Proposed rule. Fed Regist 63: 64222-64228
15. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M et al 2002 Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90: 1084-1091
16. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB 2004 Efficacy and safety of czetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79: 620-629
17. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J 1998 Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 82: 61-65
18. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A et al 2003 Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 91: 418-424
19. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP 2003a Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 57: 363-368
20. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ et al 2003b Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24: 729-741
21. Kosoglou T, Meyer I, Musiol B, Anderson L, Reyderman L, Statkevich P et al 2001 Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications [abstract]. Athero Suppl 2: 89
22. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y et al 2002 Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 54: 309-319
23. Kosoglou T, Statkevich P, Meyer I, Cutler DL, Musiol B, Yang B et al 2004a Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin 20: 955-965
24. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T et al 2004b Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 20: 1185-1195
25. Mauro VF 1993 Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24: 195-202
26. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A et al 2003 Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 24: 717-728
27. Merck/Schering-Plough Pharmaceuticals, North Wales, PA 2004 Vytorin (ezetimibe/simvastatin) tablet - prescriber information
28. MRC/BHF Heart Protection Study 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
29. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y et al 2002 Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30: 430-437
30. Pearson TA, Laurora I, Chu H, Kafonek S 2000 The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160: 459-467
31. Reyderman L, Statkevich P, Kosoglou T, Pember L, Maxwell SE, Caceres M et al 2001 No pharmacokinetic drug interaction between ezetimibe and either cerivastatin or fluvastatin [abstract]. American Association of Pharmaceutical Scientists Pharm Sci 3: AAPS
32. Reyderman L, Kosoglou T, Boutros T, Seiberling M, Statkevich P 2004 Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Curr Med Res Opin 20: 1493 -1500
33. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009
34. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307
36. Statkevich P, Zhu Y, Kosoglou T, Affrime MB, Salfi M, Patrick J et al 2000 SCH 58235 does not affect the pharmacokinetics of simvastatin [abstract]. Clin Pharmacol Ther 67: 146
37. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357
38. The Scandinavian Simvastatin Survival Study (4S) 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
39. van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB et al 1997 In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283: 157-163
40. Zhao JJ, Xie IH, Yang AY, Roadcap BA, Rogers JD 2000 Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrom 35: 1133-1143
41. Zhao JJ, Yang AY, Rogers JD 2002 Effects of liquid chromatography mobile phase buffer contents on the ionization and fragmentation of analytes in liquid chromatographic/ionspray tandem mass spectrometric determination. J Mass Spectrom 37: 421-433